[An impact of pronoran on cognitive and affective disorders in Parkinson's disease].
Sixty patients with different types of Parkinson's disease (PD), the disease stage 2.3 +/- 0.08 according to Hoehn&Yahr scale, were treated with Pronoran. Impact of the drug on movement, cognitive and affective disorders assessed by corresponding scales and psychological tests has been studied. Pronoran exerted a positive effect on all the disorders. It improved cognitive function, i.e. reasoning, memory and attention. A more pronounced influence on cognitive function was detected in earlier stages of the disease and for less severity cases of rigid-tremor PD type. A moderate antidepressive effect of Pronoran was found, being more pronounced in the severe PD stages. Emotional disorders were better treated, when Pronoran was used in combination with madopar, and cognitive dysfunction--in case of monotherapy.
Pilipovich
A A
AA
Golubev
V L
VL
D000328:Adult; D000339:Affect / Q000187:drug effects*; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000150:complications* / Q000175:diagnosis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000150:complications* / Q000175:diagnosis; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D010891:Piribedil / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011788:Quality of Life / Q000523:psychology; D012720:Severity of Illness Index; D014202:Tremor / Q000175:diagnosis / Q000209:etiology
D000978:Antiparkinson Agents; D010891:Piribedil